Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Clinical trial supports liraglutide compared to sitagliptin in treatment of type 2 diabetes

Findings from a clinical trial comparing Victoza (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to liraglutide provided superior HbA1c reductions compared to continuing with sitagliptin treatment in adults with type 2 diabetes.

 Findings from a clinical trial comparing Victoza (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to liraglutide provided superior HbA1c reductions compared to continuing with sitagliptin treatment in adults with type 2 diabetes. The results were taken from the LIRA-SWITCH trial and were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, Massachusetts. The 26-week LIRA-SWITCH trial assessed the efficacy and safety of liraglutide as an add-on to metformin in 407 adults with type 2 diabetes who switched from sitagliptin. Of the 407 adults uncontrolled on

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy